CHI3L1 and neoplasm: Pair-wise combinations of markers have identified epidermal growth factor receptor variant III (EGFRvIII) and YKL-40 as prognostically important in patients with glioblastoma, providing patients with EGFRvIII-negative/YKL-40-negative tumours with the best prognosis [29].